Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2021 Apr 1;45(4):498-506.
doi: 10.1097/PAS.0000000000001612.

Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study

Affiliations
Multicenter Study

Clinicopathologic Characteristics of Mesonephric Adenocarcinomas and Mesonephric-like Adenocarcinomas in the Gynecologic Tract: A Multi-institutional Study

Jennifer Pors et al. Am J Surg Pathol. .

Abstract

Mesonephric adenocarcinoma (MA) and mesonephric-like adenocarcinoma (MLA) are uncommon neoplasms of the gynecologic tract that have until recently been poorly understood. Although their morphologic, immunohistochemical, and molecular profiles have been recently defined, little is known about their clinical behavior. Small studies have demonstrated inconsistent findings and no large studies have examined the clinical behavior of these adenocarcinomas. In this multi-institutional study, representing the largest and most stringently defined cohort of cases to date, we examined the clinicopathologic features of 99 MAs and MLAs (30 MAs of the uterine cervix, 44 MLAs of the endometrium, and 25 MLAs of the ovary). Only tumors with characteristic mesonephric morphology and either immunohistochemical or molecular support were included. Our results demonstrate that the majority of mesonephric neoplasms presented at an advanced stage (II to IV) (15/25 [60%] MA of the cervix, 25/43 [58%] MLA of the endometrium, and 7/18 [39%] MLA of the ovary). The majority (46/89 [52%] overall, 12/24 [50%] MA of the cervix, 24/41 [59%] MLA of the endometrium, and 10/24 [42%] MLA of the ovary) developed recurrences, most commonly distant (9/12 [75%] MA of the cervix, 22/24 [92%] MLA of the endometrium, and 5/9 [56%] MLA of the ovary). The 5-year disease-specific survival was 74% (n=26) for MA of cervix, 72% (n=43) for MLA of endometrium, and 71% (n=23) for MLA of ovary. Our results confirm that mesonephric neoplasms are a clinically aggressive group of gynecologic carcinomas that typically present at an advanced stage, with a predilection for pulmonary recurrence.

PubMed Disclaimer

Conflict of interest statement

Conflicts of Interest and Source of Funding: The authors have disclosed that they have no significant relationships with, or financial interest in, any commercial companies pertaining to this article.

Figures

FIGURE 1.
FIGURE 1.
Summary of clinicopathologic features of mesonephric neoplasms. Abbreviations: ND: not done; AUB: abnormal uterine bleeding; PMB: postmenopausal bleeding; APP: abdominal or pelvic pain; Cx: cervical; AGC: atypical glandular cells; Dx: diagnosis.
FIGURE 2.
FIGURE 2.
Kaplan- Meier overall survival (OS) (A) and progression-free survival (PFS) (B) analysis for mesonephric carcinoma of the cervix versus other cervical adenocarcinomas from the same institution. Abbreviations: CI: confidence interval; HR: hazard ratio; HPVA: human papilloma virus associated; HPVI: human papilloma virus independent; MA: mesonephric adenocarcinoma.
FIGURE 3.
FIGURE 3.
Kaplan- Meier overall survival (OS) (A) and progression-free survival (PFS) (B) analysis for mesonephric-like endometrial carcinoma versus other endometrial carcinomas from TCGA endometrial database. Abbreviations: CI: confidence interval; HR: hazard ratio. MMMT: malignant mixed Mullerian tumor; EEC: endometrioid endometrial adenocarcinoma (grade 1, 2, 3); MLA: mesonephric-like adenocarcinoma.
FIGURE 4.
FIGURE 4.
The classic architectural patterns of mesonephric carcinoma are tubular (A) and glandular (B). Two patients in our study had reported histories of endometrial hyperplasia. Upon review, one case, which was originally diagnosed as simple hyperplasia, was reclassified as an incipient focus of mesonephric carcinoma (C) with concordant GATA 3 positivity (focal) (D) and ER negativity (E), while the second was confirmed to be complex atypical hyperplasia bordering on low grade endometrioid endometrial carcinoma (F), with concordant GATA3 negativity (G) and ER positivity (H), suggesting a possible Mullerian origin in a subset of mesonephric neoplasms.

References

    1. McFarland M, Quick CM & McCluggage WG Hormone receptor-negative, thyroid transcription factor 1-positive uterine and ovarian adenocarcinomas: report of a series of mesonephric-like adenocarcinomas. Histopathology. 2016; 68, 1013–1020. - PubMed
    1. Clement PB, Young RH, Keh P et al. Malignant mesonephric neoplasms of the uterine cervix. A report of eight cases, including four with a malignant spindle cell component. Am J Surg Pathol. 1995; 19, 1158–1171. - PubMed
    1. Na K & Kim HS Clinicopathologic and Molecular Characteristics of Mesonephric Adenocarcinoma Arising From the Uterine Body. Am J Surg Pathol. 2019; 43, 12–25. - PMC - PubMed
    1. Dierickx A, Göker M, Braems P et al. Mesonephric adenocarcinoma of the cervix: Case report and literature review. Gynecol Oncol Rep. 2016; 17, 7–11. - PMC - PubMed
    1. Kolin DL, Costigan DC, Dong F, et al. A Combined Morphologic and Molecular Approach to Retrospectively Identify KRAS-Mutated Mesonephric-like Adenocarcinomas of the Endometrium. Am J Surg Pathol. 2018. - PubMed

Publication types

MeSH terms

Substances